ReShape Lifesciences Inc. (RSLS) Financial Statements (2026 and earlier)

Company Profile

Business Address 1001 CALLE AMANECER
SAN CLEMENTE, CA 92673
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6934,4593,85522,7653,90514,055
Cash and cash equivalent6934,4593,85522,7653,90514,055
Receivables1,0001,700(410)(1,172)3,150285
Inventory, net of allowances, customer advances and progress billings2,4603,7413,6113,003 1,936
Inventory2,4603,7413,6113,003 1,936
Prepaid expense33419878736  
Other current assets 126841883,9301,959
Other undisclosed current assets101722,6934,735(3,150) 
Total current assets:4,58810,2969,91130,2557,83518,235
Noncurrent Assets
Operating lease, right-of-use asset1162501712665211,077
Property, plant and equipment38606981,4549571,081
Long-term investments and receivables   (100)   
Accounts and financing receivable, after allowance for credit loss   (100)   
Intangible assets, net (including goodwill)   26020,827  
Intangible assets, net (excluding goodwill)   26020,827  
Deferred income tax assets222856   
Other noncurrent assets2929461,456  
Other undisclosed noncurrent assets   100 1,304 
Total noncurrent assets:2053671,23124,0032,7822,158
TOTAL ASSETS:4,79310,66311,14254,25810,61720,393
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,8963,5036,9666,6376801,468
Employee-related liabilities 65820
Accounts payable2,2081,6891,9263,468615648
Accrued liabilities1,6881,8145,0403,169  
Deferred revenue      424
Debt 811    561
Other liabilities     3,8021,524
Other undisclosed current liabilities278274515694564 
Total current liabilities:4,9853,7777,4817,3315,0463,977
Noncurrent Liabilities
Long-term debt and lease obligation     868567
Long-term debt, excluding current maturities     430 
Liabilities, other than long-term debt 41151 55538 
Deferred income tax liabilities    555  
Other liabilities     38 
Operating lease, liability 41151  438567
Other undisclosed noncurrent liabilities 2072 300  
Total noncurrent liabilities: 61223 855906567
Total liabilities:5,0464,0007,4818,1865,9524,544
Equity
Equity, attributable to parent(253)6,6633,66146,0724,66515,849
Common stock  2311888
Additional paid in capital642,555642,302627,935622,906189,421188,271
Accumulated other comprehensive loss(104)(88)(88)(92)  
Accumulated deficit(642,704)(635,574)(624,187)(576,760)(184,764)(172,430)
Total equity:(253)6,6633,66146,0724,66515,849
TOTAL LIABILITIES AND EQUITY:4,79310,66311,14254,25810,61720,393

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues8,0068,67811,24013,6001,5883,281
Cost of revenue(2,949)(3,130)(4,438)(5,252)(1,004)(2,950)
Cost of product and service sold(2,949)(3,130)(4,438)(5,252)(1,004) 
Gross profit:5,0575,5486,8028,348584331
Operating expenses(12,785)(20,931)(53,153)(64,849)(12,536)(23,561)
Operating loss:(7,728)(15,383)(46,351)(56,501)(11,952)(23,230)
Nonoperating income (expense)142144(130)168(411)(61)
Gain (loss), foreign currency transaction, before tax(51)22(141)168  
Other nonoperating income (expense)19312211 (411)(61)
Interest and debt expense429  (2,061)  
Loss from continuing operations before equity method investments, income taxes:(7,157)(15,239)(46,481)(58,394)(12,363)(23,291)
Other undisclosed income (loss) from continuing operations before income taxes663,904(113)(3,645)  
Loss from continuing operations before income taxes:(7,091)(11,335)(46,594)(62,039)(12,363)(23,291)
Income tax expense (benefit)(39)(52)380106  
Loss from continuing operations:(7,130)(11,387)(46,214)(61,933)(12,363)(23,291)
Loss before gain (loss) on sale of properties:(61,933)(12,363)(23,291)
Net loss:(7,130)(11,387)(46,214)(61,933)(12,363)(23,291)
Other undisclosed net income (loss) attributable to parent     29(385)
Net loss available to common stockholders, diluted:(7,130)(11,387)(46,214)(61,933)(12,334)(23,676)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(7,130)(11,387)(46,214)(61,933)(12,363)(23,291)
Comprehensive loss:(7,130)(11,387)(46,214)(61,933)(12,363)(23,291)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(16) 42929(385)
Comprehensive loss, net of tax, attributable to parent:(7,146)(11,387)(46,210)(61,904)(12,334)(23,676)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: